Seven world-renowned cardiac surgeons and interventional cardiologists have joined Xeltis’ newly appointed Clinical Advisory Board, uniting premium talent from Europe and the US to support the clinical development of the first ETR-enabling bioabsorbable heart valves and blood vessels. The clinicians work in global medical institutions at the forefront of innovation in cardiovascular medicine and particularly in minimally invasive heart valve therapies and include:
• Professor Thierry Carrel, Director of the Department of Cardiovascular Surgery, University Hospital, Bern, Switzerland
• Professor Volkmar Falk, Medical Director and Director of the Department of Cardiothoracic and Vascular Surgery, German Heart Institute Berlin and Charité, Berlin, Germany
• Martin Leon, MD, Director of the Center for Interventional Vascular Therapy at Columbia University Medical Center / New York-Presbyterian Hospital, New York, NY, USA
• Michael Mack, MD, Medical Director of Cardiovascular Surgery, Baylor Health Care System and Chairman of the Heart Hospital Baylor Plano Research Center, Plano, TX, USA
• Professor Francesco Maisano, Head of Cardiovascular Surgery, Zurich University Hospital, Zurich, Switzerland
• Professor Christian Spaulding, Professor of Cardiology, Paris-Descartes University and Director of the Interventional Cardiology Department, European Hospital Georges Pompidou, Paris, France
• Professor Stephan Windecker, Director and Chief Physician of the Department of Cardiology, Swiss Cardiovascular Center, University Hospital, Bern, Switzerland
“We are committed to delivering game-changing cardiovascular innovations and making ETR an available treatment option through our technology,” commented Xeltis CEO Laurent Grandidier, “The expertise of our advisory board confirms the interest of the cardiovascular community in Xeltis’ technology and better equips us to deliver it.”
Learn more about ETR
